Altimmune Management
Management criteria checks 2/4
Altimmune's CEO is Jerry Durso, appointed in Jan 2026, has a tenure of less than a year. directly owns 0.01% of the company’s shares, worth $58.12K. The average tenure of the management team and the board of directors is 3 years and 6.5 years respectively.
Key information
Jerry Durso
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.01% |
| Management average tenure | 3yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026
Feb 03Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
Mar 17Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Feb 28Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Feb 18Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?
Jan 15
Altimmune Could Find A Partner For Its Phase 3 Exercise
Dec 30Altimmune 2025: Redefining Obesity And MASH Treatment
Dec 16Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Nov 13Regulatory And Clinical Catalysts Ahead For Altimmune
Oct 28Consider Buying Potential Takeover Target Altimmune
Oct 02Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Jun 24Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
May 27Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12CEO
Jerry Durso (57 yo)
Mr. Jerome Benedict Durso, also known as Jerry, is Chief Executive Officer and President of Altimmune, Inc. since January 1, 2026 and serves as its Chairman. He was Independent Director of Altimmune, Inc....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Scientific Officer | 13.2yrs | US$2.42m | 0.090% $ 524.6k | |
| Chairman | less than a year | no data | 0.010% $ 58.1k | |
| Chief Financial Officer | 1.3yrs | no data | 0.018% $ 107.3k | |
| Principal Financial & Accounting Officer and Corporate Controller | 3yrs | no data | 0.0091% $ 52.9k | |
| Chief Technology Officer | 8.8yrs | no data | no data | |
| Vice President of Quality & Compliance Management | 4yrs | no data | no data | |
| General Counsel & Chief Legal Officer | no data | no data | no data | |
| Chief Business Officer | 3.1yrs | US$2.94m | 0.056% $ 326.0k | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: ALT's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 1yr | no data | 0.010% $ 58.1k | |
| Independent Director | 15.8yrs | US$255.24k | 0.021% $ 122.6k | |
| Independent Director | 21.5yrs | US$239.24k | 0.010% $ 58.1k | |
| Director | 7.3yrs | US$6.09m | 0.34% $ 2.0m | |
| Independent Director | 8.8yrs | US$251.24k | 0.0070% $ 40.6k | |
| Independent Director | 8.8yrs | US$240.24k | 0.0073% $ 42.7k | |
| Independent Director | 2.9yrs | US$233.99k | 0.0012% $ 7.0k | |
| Independent Director | 7.5yrs | US$244.24k | 0.011% $ 62.8k | |
| Independent Director | 5.8yrs | US$231.24k | 0.00042% $ 2.4k | |
| Member of Mash Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Mash Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Mash Scientific Advisory Board | 3.6yrs | no data | no data |
Experienced Board: ALT's board of directors are considered experienced (6.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 14:41 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Altimmune, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |
| Jonathan Wolleben | Citizens JMP Securities, LLC |